Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency
Gusev EI, Skvortsova VI, Chukanova EI. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova 2005;105:35-40.
What it found
The authors reported clinical improvement, slower disease progression, a lower risk of stroke and transient ischaemic attacks, and few side effects, including in older patients.
Limitations
Article in Russian. The abstract gives no numbers, no description of a control group and no information on randomisation or blinding.
Research and education only. Not medical advice. Many peptides on this site are not approved by the FDA for human use. Doses shown are the ones used in published studies and are not a recommendation. Talk to a licensed clinician before using any of them. Read the full disclaimer.